Brian McLellan Promoted To President Of Astellas Pharma US

Brian McLellan Promoted To President Of Astellas Pharma US

NORTHBROOK, Ill., Oct. 1, 2014 /PRNewswire/ -- Astellas has appointed Brian McLellan as the president of Astellas Pharma Technologies in the Americas region. In this role, Brian will be responsible for managing all operations at the Norman, OK facilities. He will also be responsible for ensuring the continuous cost-effective and controlled manufacturing of products in compliance with all internal Astellas policies and all governmental regulations. McLellan will report directly to Scott Aladeen, head of the US technology division, president of Astellas US Technologies.

Astellas is a pharmaceutical company dedicated to improving the health of people around the world.
McLellan has been promoted to his current position from vice president of technology and operations at Astellas Pharma Technologies. He joined Yamanouchi one of Astellas' two founding companies in 1997 as a project manager in business development. Since then, he has held roles of increasing responsibility in the areas of manufacturing and technology. Prior to joining Astellas, McLellan worked in research & development at Shaklee U.S. Inc. He holds a bachelor's degree in management from Saint Mary's College of California.

"Brian has had great success throughout his career at Astellas and his strong leadership skills and experience in the industry will prove to be an asset to the team," said Aladeen. "Brian will be responsible for ensuring that patients who need our medications will receive the highest quality product possible."

About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS.

Logo - http://photos.prnewswire.com/prnh/20140416/84970

SOURCE Astellas Pharma US, Inc.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.